IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly

15 June 2016

Biosimilar Medicines for Rheumatologists: Bridging the Gap between Regulatory Science and Medical Societies

10 June 2016

Over the past decade, biosimilar medicines have generated more than […]

Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines Agenda

9 June 2016

During the next two days, the key pharmaceutical industry leaders […]

Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation / 10th June 2016, 08:15–09:45 Capital Suite 09, ExCel London

17 May 2016

10 Years of Biosimilar Medicines: Transforming Healthcare

28 April 2016

Biosimilar medicines provide an opportunity to increase patient access to […]

6 out of 10 Doctors Have Already Prescribed Biosimilar Medicines, According to EuropaBio Paper

20 April 2016

Medicines for Europe and its Biosimilar Medicines Group took note […]

Medicines for Europe Reinforces its Commitment to Promote Universal Access to Health

19 April 2016

Over 100 participants will explore different ways and opportunities to […]

100% increase in Patient Access to Biologic Treatments thanks to Biosimilar Medicines

30 March 2016

Biosimilar medicines represent an essential opportunity to optimise patient access to […]

EGA becomes Medicines for Europe

10 March 2016

The European Generic and Biosimilar Medicines Association is now Medicines […]

IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

2 March 2016